PatientsVille.com Logo


Acute Medical Research Studies

Up-to-date List of Acute Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Acute Medical Research Studies

Rank Status Study
1 Recruiting BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
Condition: Acute Coronary Syndrome
Intervention: Drug: Acetylsalicylic acid (Aspirin, BAY 81-8781)
Outcome Measures: The primary efficacy variable will be the TXB2 (Thromboxane B2) concentration at 5 minutes after study drug administration.;   TXB2 (Thromboxane B2) values at 20 minutes;   Platelet aggregation inhibition;   Serum prostacyclin levels;   Incidence of post randomization deaths from all causes, cardiovascular deaths, myocardial re/infarctions and ischemic strokes;   Safety laboratory examinations, vital signs, physical examination, ECG, adverse events collection;   Incidence of all post randomization strokes of unknown etiology;   Incidence of all post randomization bleedings assessed according to the TIMI (thrombolysis in myocardial infarction) classification including hemorrhagic stroke;   Hospital mortality during the hospitalization for ACS (Acute Coronary Syndrome)
2 Recruiting Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy -- Use in Acute Cholecystitis Sub-Study
Conditions: Acute Cholecystitis;   Acute Cholangitis
Interventions: Drug: Indocyanine Green (ICG);   Device: Near Infrared Fluorescence Cholangiography (NIRF-C)
Outcome Measures: Adverse events related to use of indocyanine green (ICG);   Anatomic identification with NIRF-C and IOC;   Procedure time
3 Recruiting Clinical Characteristic of Recurrent Acute Rhinosinusitis in Children
Condition: Acute Recurrent Sinusitis
Intervention: Other: Recurrent Acute Rhinosinusitis
Outcome Measures: Presenting symptoms of recurrent Acute rhinosinusitis;   Age of onset
4 Recruiting Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: allogeneic bone marrow transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
Outcome Measures: Maximum tolerated dose (MTD) of 131 I-BC8 antibody defined as the dose that is associated with a true dose limiting toxicity (DLT) rate of 25%, graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3;   Rates of immune reconstitution;   Rates of engraftment;   Rates of donor chimerism;   Rates of Acute GVHD;   Rates of disease-free survival;   Rates of disease relapse;   Disease-free survival;   Overall survival
5 Recruiting Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury
Conditions: Acute Lung Injury;   Acute Respiratory Distress Syndrome
Outcome Measures: Development of ALI;   Quality adjusted survival
6 Recruiting Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Conditions: Relapsed Acute Lymphoblastic Leukemia;   Relapsed Acute Myelogenous Leukemia
Intervention: Drug: GNKG168
Outcome Measures: Number of patients with dose limiting toxicity (DLT).;   To measure the reduction of MRD in patients treated with GNKG168.;   To measure the length or remission in patients who receive GNKG168.;   To measure the rate of Graft Versus Host Disease (GVHD) in patient with previous HSCT.;   To measure the rate graft failure in patients who previously had a HSCT and who received GNKG168.
7 Recruiting Efficacy of Hydrocortisone in Treatment of Severe Sepsis/Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Conditions: Septic Shock;   Severe Sepsis;   Acute Lung Injury;   Acute Respiratory Distress Syndrome
Interventions: Drug: Placebo;   Drug: Hydrocortisone
Outcome Measures: All cause mortality;   Ventilator free day;   Vasopressor free day;   Rate of renal replacement therapy;   Organ support free days
8 Recruiting Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia
Interventions: Biological: pretargeted radioimmunotherapy;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: fludarabine phosphate;   Other: pharmacological study
Outcome Measures: Incidence of dose-limiting toxicities (DLT) (Grade III/IV Bearman) to determine MTD of radiation delivered to normal organ by pretargeted 90Y-DOTA-biotin;   Rates of engraftment, chimerism, and non-relapse mortality;   Rate of grades III-IV Acute GVHD;   Achievement and duration of response
9 Recruiting Study of ABSORB Stent in Acute Myocardial Infarction
Conditions: Acute Myocardial Infarction;   Artery; Deformity, Coronary (Acquired)
Intervention: Procedure: angioplasty
Outcome Measures: MACE (Death, MI, TLR and TVR);   Acute stent Recoil
10 Recruiting Very Early veRsus Deferred Invasive Evaluation Using Computerized Tomography in Patients With Acute Coronary Syndromes
Condition: Coronary Artery Disease
Interventions: Procedure: Invasive coronary evaluation (Deferred);   Procedure: Invasive coronary evaluation (Acute)
Outcome Measures: Composite clinical endpoint;   Bleeding;   Non-bleeding, invasive procedure related complications;   Death;   Non-fatal Acute myocardial infarction;   Hospital admittance due to refractory myocardial ischemia (Acute coronary syndrome);   Repeat coronary revascularization;   Hospital admittance due to left ventricular heart failure;   GRACE Risk Score
11 Recruiting Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery
Conditions: Acute Kidney Injury;   Cardiac Surgery
Interventions: Drug: Sodium Bicarbonate;   Drug: Sodium Chloride
Outcome Measures: Acute Kidney Injury;   Duration of Acute kidney injury;   Cumulative fluid balance;   Hospital and intensive care unit length of stay;   Need for dialysis;   Incidence of Acute kidney injury according to changes in serum NGAL.;   Length of mechanical ventilation;   Change in acid-base status
12 Recruiting L-Arginine, Symmetrical and Asymmetrical Dimethylarginine (SDMA/ADMA) in Acute Kidney Injury (AKI)
Condition: Acute Kidney Injury
Outcome Measures: Difference in serum ADMA level between Acute kidney injury and renal recovery;   Difference in serum SDMA level between Acute kidney injury and renal recovery;   Associations between ADMA/SDMA serum level and all cause mortality;   Associations between ADMA/SDMA serum level and parameters of arterial stiffness;   Associations between ADMA/SDMA serum level and parameters of renal function
13 Recruiting Air Pollution, Inflammation and Acute Coronary Syndrome
Condition: Patients With Acute Coronary Syndrome
Intervention: Other: Particulate air pollutants
Outcome Measure: Impact of air pollution on inflammation, oxidative stress and 1-year prognosis in patients hospitalized for Acute coronary syndrome.
14 Recruiting Predicting Acute Kidney Injury After Coronary Artery Bypass Graft
Conditions: Coronary Artery Bypass Surgery;   Acute Kidney Injury;   Creatinine;   Mortality
Intervention: Procedure: Coronary artery bypass surgery
Outcome Measures: Acute kidney injury diagnosis defined by RIFLE criteria;   Acute kidney injury as defined by AKIN (Acute kidney injury network) criteria
15 Recruiting Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury
Condition: Kidney Failure, Acute
Intervention: Procedure: Acute extra renal replacement therapy
Outcome Measures: extra renal replacement therapy;   Current incidence;   etiologies;   Risk factors of mortality and non recovery of the renal function
16 Not yet recruiting Early Goal Directed Therapy for Acute Kidney Injury
Condition: Kidney Injury, Acute
Intervention: Procedure: Early goal directed therapy during 6 hours after occurence of the early phase of Acute kidney injury
Outcome Measures: Observation of Acute kidney injury;   Organ failure during first 48 hours and during stay on intensive care unit;   Duration of stay on intensive care unit and in hospital;   Mortality during stay on intensive care unit
17 Recruiting China Acute Myocardial Infarction Registry
Condition: Acute Myocardial Infarction
Outcome Measures: In-hospital mortality of the patients with Acute myocardial infarction in different-level hospitals across China;   The rate of the application of thrombolysis and primary percutaneous coronary intervention for Chinese patients with Acute myocardial infarction in different-level hospitals;   provoking factors of Chinese patients with AMI across different areas and different population in China
18 Recruiting Pulmonary And Renal Support During Acute Respiratory Distress Syndrome
Conditions: Acute Respiratory Distress Syndrome;   Acute Renal Failure
Intervention: Device: Combined ECCOR and RRT
Outcome Measures: Arterial carbon dioxide reduction;   Gas transfer measurement;   Arterial blood gases;   carbon dioxide elimination (VCO2);   Respiratory mechanics and hemodynamic parameters;   Safety monitoring
19 Recruiting Echocardiography Predictive of the Inefficacy and/or of the Unsafeness of Recruitment Maneuvers in Patients With Acute Respiratory Distress Syndrome.
Condition: Acute Respiratory Distress Syndrome
Intervention: Device: Echocardiography
Outcome Measures: Efficacy and safety of recruitment maneuvers in patients with Acute Respiratory Distress Syndrome.;   Feasibility of the measurement of Longitudinal Strain and Strain Rate of the right ventricle in patients suffering from Acute Respiratory Distress Syndrome.;   Comparison of the results of echocardiographic measurements between the group CONTROL and the group FAILURE.;   Evaluate the effect of the inefficacy and/or of the unsafeness of the recruitment maneuver on the future of the patient suffering from Acute Respiratory Distress Syndrome.
20 Recruiting Acute Lymphoblastic Leukemia Registry at Asan Medical Center
Conditions: Leukemia, Acute Lymphoblastic;   Precursor B-Cell Lymphoblastic Leukemia;   Leukemia, Biphenotypic, Acute;   Leukemia, Lymphoblastic, Acute, Philadelphia-Positive;   Lymphoblastic Lymphoma
Intervention: Other: Diagnosed as ALL
Outcome Measures: Overall survival;   Event-free survival;   Relapse-free survival

These studies may lead to new treatments and are adding insight into Acute etiology and treatment.

A major focus of Acute research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Acute